The Law Office of Joseph Klein is investigating the Board of Directors of Genoptix, Inc. (Nasdaq: GXDX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Novartis AG (“Novartis”) (NYSE: NVS). Under the terms of the transaction, Genoptix shareholders will receive $25.00 cash for each share of Genoptix common stock they own, for a total transaction value of approximately $470 million.

The investigation concerns whether the Genoptix Board of Directors breached their fiduciary duties to Genoptix stockholders by failing to adequately shop the Company before entering into this transaction and whether Novartis is underpaying for Genoptix shares. At least one analyst set a price target of $28.00 per share and Genoptix stock traded as high as $38.79 per share as recently as April 30, 2010.

If you own common stock in Genoptix and wish to obtain additional information, please contact Joseph Klein, Esq. directly, via email at, by telephone at 718-947-0005, Toll Free: 877-STOK-180, or visit

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010